In a report released today, Iain Simpson from Barclays maintained a Buy rating on Haleon PLC (HLN – Research Report), with a price target ...

In a report released today, Guillaume Delmas from UBS maintained a Buy rating on Haleon PLC (HLN – Research Report), with a price target ...

Haleon is teaming up with the University of Sydney to launch a five-year fellowship to research the efficacy of dietary supplements for ...

Futura Medical, the consumer healthcare company behind Eroxon, announced on Monday that a $5m milestone payment had been ...

Pfizer sold 640 million shares in Haleon for 380p each, reducing its holding in the consumer healthcare firm by 7.6% ...

Haleon plc (LSE/NYSE: HLN), a global consumer health company, disclosed today that Alan Stewart has resigned from its board of directors. Stewart's departure was effective as of Sunday ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

Pfizer sold a stake in British consumer healthcare group Haleon worth about $3.26 billion on Monday, cutting its shareholding ...

Goldman Sachs raises AstraZeneca price target to 16,046 (15,914) pence - 'buy' Barclays raises Standard Chartered price target to 890 (850) pence - 'equal weight' Barclays raises Harbour Energy price ...

Pfizer is in value territory, trading at just 10.74X forward earnings with a 5.88% annual dividend yield and over $10 billion in cash after selling $2.4 billion of its HLN position.

From Tesla's persisting problems to Formula One and LVMH's latest 10-year long tie-up, here's a look at some of the major ...